Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis

Drug May Reach Market In 2025, After Olezarsen

Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.

London, UK. 3rd January 2024. Horse racing events in the UK.
Targeting APOC3 is a two-horse race in hypertriglyceridemia • Source: Shutterstock

Arrowhead Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. both aim to bring their first wholly owned drugs to market for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), with Ionis’s olezarsen in the leading position. But Arrowhead outlined a new plan to focus all of its late-stage cardiovascular disease development efforts on its FCS and SHTG drug plozasiran, which means the company will seek a partner to pursue Phase III development of its other late-stage cardiovascular candidate, zodasiran.

Key Takeaways

  • Arrowhead will focus on its RNAi drug plozasiran for Phase III development but seek a partner for its other Phase III-ready cardiovascular disease candidate zodasiran.

Pasadena, CA-based Arrowhead outlined its Phase III program for plozasiran and revealed its partnering plan for zodasiran during a cardiometabolic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category